GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Obio Technology (shanghai) Corp Ltd (SHSE:688238) » Definitions » Debt-to-EBITDA

Obio Technology (shanghai) (SHSE:688238) Debt-to-EBITDA : -1.38 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Obio Technology (shanghai) Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Obio Technology (shanghai)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥198.5 Mil. Obio Technology (shanghai)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥120.0 Mil. Obio Technology (shanghai)'s annualized EBITDA for the quarter that ended in Mar. 2025 was ¥-231.3 Mil. Obio Technology (shanghai)'s annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -1.38.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Obio Technology (shanghai)'s Debt-to-EBITDA or its related term are showing as below:

SHSE:688238' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67   Med: -0.62   Max: 1.97
Current: -1.02

During the past 11 years, the highest Debt-to-EBITDA Ratio of Obio Technology (shanghai) was 1.97. The lowest was -1.67. And the median was -0.62.

SHSE:688238's Debt-to-EBITDA is ranked worse than
100% of 283 companies
in the Biotechnology industry
Industry Median: 1.36 vs SHSE:688238: -1.02

Obio Technology (shanghai) Debt-to-EBITDA Historical Data

The historical data trend for Obio Technology (shanghai)'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Obio Technology (shanghai) Debt-to-EBITDA Chart

Obio Technology (shanghai) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 1.97 1.32 -1.67 -0.98

Obio Technology (shanghai) Quarterly Data
Jun19 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.27 -1.02 -0.74 -0.44 -1.38

Competitive Comparison of Obio Technology (shanghai)'s Debt-to-EBITDA

For the Biotechnology subindustry, Obio Technology (shanghai)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Obio Technology (shanghai)'s Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Obio Technology (shanghai)'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Obio Technology (shanghai)'s Debt-to-EBITDA falls into.


;
;

Obio Technology (shanghai) Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Obio Technology (shanghai)'s Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(87.868 + 127.569) / -219.867
=-0.98

Obio Technology (shanghai)'s annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(198.547 + 120.023) / -231.272
=-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Obio Technology (shanghai)  (SHSE:688238) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Obio Technology (shanghai) Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Obio Technology (shanghai)'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Obio Technology (shanghai) Business Description

Traded in Other Exchanges
N/A
Address
Lane 908, Ziping Road, Building 19, International Medical Park, Pudong New Area, Shanghai, CHN, 201321
Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Executives
You Qing Rui Directors, senior managers
Pan Jun Yi Director
Yang Jia Li Core technical personnel

Obio Technology (shanghai) Headlines

No Headlines